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Received 16 July 2012; accepted 23 July 2012Familial amyloidotic polyneuropathy (FAP) is a hereditary
polyneuropathy caused by transthyretin (TTR) mutation,
and characterized by length-dependent sensorimotor pol-
yneuropathy, autonomic dysfunction, and visceral organ
involvement.1 TTR is a tetrameric protein with binding sites
for thyroxine and retinol-binding protein (RBP)/vitamin A
complex. About 100 different disease-causing mutations of
the TTR gene have been reported. The most common
mutation worldwide is Val30Met, which is endemic in
Portugal, Sweden and Japan.1 Here, we report a Taiwanese
FAP family with a rare TTR mutation, Phe33Leu.
A 50-year-old man presented with intractable diarrhea
since the age of 47. Orthostatic dizziness, erectile
dysfunction, anhidrosis and hyperalgesia in the distal parts,
and limb weakness developed in the following 3 years.
There were no similar symptoms among his parents and
siblings. Neurological examination revealed muscle wasting
with weakness of the limbs, generalized areflexia, hyper-
algesia in a glove-stocking distribution, and unsteadiness
with a positive Romberg’s test. Prominent orthostatic
hypotension was documented (blood pressure Z 116/
75 mmHg in the supine position and 67/50 mmHg upon
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relevant to this article.
* Corresponding author. Department of Neurology, National
Taiwan University Hospital, Number 7, Chung-Shan South Road,
Taipei, 10002, Taiwan.
E-mail address: mjlee@ntu.edu.tw (M.-J. Lee).
0929-6646/$ - see front matter Copyright ª 2012, Elsevier Taiwan LLC
http://dx.doi.org/10.1016/j.jfma.2012.07.026unremarkable. The nerve conduction study showed an
axonal type sensorimotor polyneuropathy and autonomic
dysfunction. A transthoracic echocardiogram showed
a restrictive cardiomyopathy with sparkling myocardium.
The endoscopic biopsy of gastric and intestine mucosa
confirmed the presence of amyloid fibrils.
A TTR-associated FAP was highly suspected in the index
case according to the clinical features. Sequencing of the
human TTR gene identified a heterozygous transversion
of ‘T’ to ‘C’ at nucleotide 183 (Fig. 1A), predicted to
a Phe33Leu change. No similar change was observed in
200 Taiwanese controls. Furthermore, Phe33 is highly
conserved in vertebrate species (Fig. 1A). Molecular
mimicry demonstrated that the mutated TTR had a reduced
size of the cleft in the surface receptor for RBP/vitamin A
complex binding (Fig. 1B). The patient’s two asymptomatic
daughters also harbored the same mutation.
The Phe33 is a highly conserved amino acid of the TTR
protein during evolution. The replacement of the aromatic
ring associated with phenylalanine for leucine could cause
a conformational change in the TTR protein, which may
lead to destabilization of the tetrameric molecule, further
resulting in the formation of amyloid fibrils.2 Whether an
alteration in the distance across the surface receptor for
RBP/vitamin A plays a role in amyloidogenic TTR formation
needs further investigation.
To date, the TTR Phe33Leu mutation has only been re-
ported in four families, originating from the Baltic states
and Scandinavia: two un-related Polish-American fami-
lies,3,4 one Polish-Lithuanian family,2 and one Swedish& Formosan Medical Association. All rights reserved.
Figure 1 Phe33Leu mutation in the transthyretin (TTR) gene. (A) The sequence chromatography demonstrates a ‘T’ to ‘C’ change
(arrow) which results in the replacement of phenylalanine for leucine (upper panel). The phenylalanine 33 is a conserved amino
acid (arrow) across species; (B) molecular mimicry using the Discovery Studio V 2.5 (DS V2.5) software (DS, Accelrys, San Diego, CA,
USA) to depict the tetramer of the TTR which demonstrates a shortening of the distance between the mutant amino acid ‘LeueLeu’
(16.0 A˚) compared with the wild type ‘PheePhe’ (18.2 A˚).
576 C.-H. Chen et al.family.5 Thus, this is the first case with a TTR Phe33Leu
mutation from the Asian populations. The clinical features
of the disease in our patient (i.e., mid-aged onset, axonal
type sensorimotor polyneuropathy, cardiomyopathy and
autonomic dysfunction) were consistent with the reported
cases. In conclusion, genetic screening for TTR-related FAP
is valuable, since pre-symptomatic genetic counseling and
novel therapeutic approaches are both important for the
affected patients and their relatives.
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